Created in partnership with Parkinson's UK, the Critical Path for Parkinson's Consortium (CPP) was launched in 2015. It is a global collaboration that facilitates collaboration among scientists from the bio-pharmaceutical industry, academic institutions, government agencies, and patient-advocacy associations. It fosters consensus and data-driven research to increase efficiency, safety, and speed in developing new therapies.
The Oxford Parkinson's Disease Centre is jointly led by Professor Michele Hu in our Department, and Professor Richard Wade-Martins from the Department of Physiology, Anatomy & Genetics.